

## **Further Latiglutenase Analyses Published in GastroHep**

### **Significant symptom and quality of life improvement in celiac disease patients**

The clinical team at ImmunogenX and its collaborators are pleased to announce the publication of the manuscript “Latiglutenase treatment for celiac disease: symptom and quality of life improvement for seropositive patients on a gluten-free diet” (Full reference: Syage JA, Green PHR, Khosla C, Adelman DC, Sealey-Voyksner JA, Murray JA. *GastroHep*. 2019;1:293–301. <https://doi.org/10.1002/ygh2.371>). *GastroHep* is an International Journal of Gastroenterology and Hepatology published by Wiley. These peer reviewed results are based on the recent ALV003-1221 trial for latiglutenase (CeliAction® Study), where we report for secondary endpoints, statistically and clinically-significant improvement for most symptoms associated with celiac disease (CD) as well as quality of life for seropositive patients on latiglutenase.

ImmunogenX has an active clinical program currently in place that should complete the company’s Phase 2 program. Three trials all funded by the National Institutes of Health are focusing on different therapeutic indications and patient populations.

Dr. Jack Syage PhD, CEO comments “We are gratified to present further promising results from the CeliAction trial, the largest clinical trial for celiac disease performed to date. The evidence for the efficacy and safety of latiglutenase is quite convincing and we anxiously await the results of our current clinical studies to further validate the results obtained for the ALV003-1221 trial leading the way to a Phase 3 registration program.”

Dr. Peter H.R. Green MD adds, “The results showing symptom and quality of life benefit in seropositive CD patients due to latiglutenase are very encouraging and give us hope that a therapy to help celiac patients struggling from gluten-induced symptoms may be achievable soon.”

### **About ImmunogenX**

ImmunogenX® (a subsidiary of Immunogenics LLC) is a clinical-stage biotherapeutics company founded in 2013 and is supported by a team of world-renowned clinicians, scientists and advisors in celiac disease research. The company is developing latiglutenase for celiac disease therapy. ImmunogenX is also developing a minimally-invasive diagnostic tool for celiac disease management (CypCel™) based on a clinically relevant metabolic marker compound that can assess the state of recovery of a celiac patient adhering to a gluten-free diet or other treatment. For food safety, ImmunogenX is pioneering advanced mass spectrometry methods to identify and measure physiologically relevant gluten peptide sequences found in wheat, barley, and rye.

[www.immunogenx.com](http://www.immunogenx.com)

### **For further information please contact**

Matthew Dickason, COO  
949 679-0900  
mdickason@immunogenx.com